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Abstract 
 The aryl hydrocarbon receptor is a ligand-activated transcription factor of the Per-
Arnt-Sim (PAS) family of proteins that regulates cellular functions including immunity. 
It has been shown that 2,3,7,8-Tetrachlorodibenzodioxin (TCDD), a high affinity ligand 
for the aryl hydrocarbon receptor (AhR), suppresses immune responses in mice. AhR ac-
tivation prior to immunization with cholera toxin results in suppression of anti-cholera 
toxin antibody responses. This is observed as lower immunoglobulin (IgA) levels in both 
feces and serum 14 days after immunization. Thereafter, cholera toxin (CT)-specific IgA 
fecal responses recover, where serum CT-specific antibody levels do not; something un-
explained by the current paradigm for AhR regulation of immune responses. Because the 
half-life of TCDD in mice is approximately 7 days, immunosuppressive TCDD levels can 
persist for multiple weeks. It is unknown if a high dose of TCDD is necessary for the sup-
pression of the fecal IgA response or if lower doses can achieve the same outcome in 
both feces and serum. The question is: does activation of the aryl hydrocarbon receptor 
via weekly, low dose exposure to TCDD cause altered IgA/IgG responses equivalent to 
that observed following a single, high dose exposure? The pertinence of this experiment 
is to better explain how the aryl hydrocarbon receptor exerts a modifying influence in dif-
ferent body compartments and how the homeostatic pattern of the AhR is related; giving 
a better understanding of how it may be exploited clinically. This question will be ad-
dressed through lab-based experimentation model outlines provided, using female 
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C57B1/6 mice. Data were collected from immunologically relevant tissues (serum) and 
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List of Abbreviations 
AhR: Aryl hydrocarbon receptor  
AOC: Area under the curve (data analytics) 
TCDD: 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
CT: Cholera toxin 
ELISA: 
OD: Optical Density  
IgA(G/M): Immunoglobulin A(G/M) 
ASC: Antibody secreting cells 
@TON: At time of necropsy 
mcg(/kg): Micrograms/ micrograms per kilogram  
 
 
Assessing TCDD Dosages   7 
 
2,3,7,8-Tetrachlorodibenzo-p-dioxin Dosing and Activating the Aryl Hydrocarbon Re-
ceptor: an Immunological Approach Assessing Cholera-Toxin Specific Antibody 
Review of Related Literature  
Organization of Immune System 
 The innate and adaptive immune systems are the two largest parts in the organiza-
tion of the immune system. The innate immune response is known as the “rapid re-
sponse” and is the first line of defense against any invader. There are three major compo-
nents to the innate response, being: barriers, patrolling cells, and soluble defense factors. 
If the innate immune system is not able to target the invader, the adaptive immune system 
is activated in addition. The adaptive immune response is the delayed response that has 
cells to secrete antibodies (plasma cells), coordinate other cells for better defense, and at-
tack self (CTL). There are two major components in adaptive immunity: being humoral 
and cell-mediated immunity; as exhibited in Figure A. Humoral immunity is antibody 
mediated and is expressed through B lymphocytes. Its mode of action is antibody secre-
tion and its primary defense is against extracellular pathogens. Cell-mediated immunity is 
expressed by T-lymphocytes and its mode of action is direct cell-to-cell contact or se-
creted cytokines. Cell-mediated immunity has a primary defense against intracellular 
pathogens; something that antibodies are not capable of doing (Alam, 1998). In summary,  
“mechanisms by which pathogen-specific innate immune recognition activates antigen-
specific adaptive immune responses and the roles of different types of innate immune 
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recognition in host defense from infection and injury” are crucial in the prospect of mor-




Antibody Secretion via Humoral Immunity 
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 Immunoglobulins/antibodies are glycoproteins secreted as a product of the hu-
moral immune response by B-cells as a way for the body to neutralize and target antigens 
(Hsu, 2018). Antigens are molecules that initiate an immune response in the body: this 
can include attachment to threatening pathogens such as viruses and bacteria, trans-
planted organs or tissues, or even self cells (autoimmunity). During B cell development 
in the bone marrow, each immature B cell produces an antigen receptor that is unique in 
its specificity. Attachment of antigen to a naive B cell receptor initiates B cell activation 
(often with helper T cell). Activated by the binding of an antigen to a specific matching 
receptor on its surface, the B cell proliferates into a clone via colonal selection of a B cell 
(Burnet 1957). Following, clonal cells differentiate producing plasma cells and memory 
B cells. Memory B cells are used for immunologic memory or secondary response. 
Plasma cells secrete antibodies/immunoglobulin that will bind to the antigen for eventual 
destruction.  
 In relation to this project directly, it has been shown that exposure to AhR agonists 
has disrupted the adaptive immune response. Additionally, for B cells, AhR activation re-
duces the probability of naive B cell commitment to IgM secretion and suppresses class 
switch recombination to IgG and IgA isotypes, whereas antibody production 
per activated B cell is unchanged, and clonal expansion is only mildly impacted (Yang, 
2014). This is supported in Figure C. Additionally, the AhR alters expression of factors 
that control antibody secreting cell (ASC) migration. 
Antibodies 
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 Self and environmental factors can influence how the body’s antibody response is 
initiated and, in turn, how much, and of what antibody isotype is produced more or less in 
response. Immunoglobulin A (IgA) is the predominant class of antibody in secretions and 
is found in mucous, saliva, tears, and blood (Parham, 2000). IgA is translocated to muco-
sal surfaces and is one of the first isotypes in defense against foreign invaders (patho-
gens) on the outside of the body. Each immunoglobulin isotype (IgA, IgG, IgM, etc.) has 
defining structures and traits that differ from the next making them most prominent in 
different areas of the body; which are exhibited in Figure B. There are two different iso-
types of IgA in humans, being IgA1 and IgA2; IgA1 being found most often in serum, 
and IgA2 being found most often in secretions (i.e. lumen of GI tract, and eventually, fe-
ces).  Each antibody is eventually attached to a singular antigen to serve as a chemical 
signal for the antibody itself, phagocytosis by macrophages, or T-lymphocytes to destroy. 
Dysregulation of antibody responses is linked to altered disease resistance and insuffi-
cient antibody can lead to morbidity and mortality. On the other hand, production of anti-
body against self can also cause morbidity and mortality. Activation of the aryl hydrocar-
bon receptor (AhR) alters antibody responses, most often by suppression.  
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 Figure B 
The Aryl Hydrocarbon Receptor  
 The aryl hydrocarbon receptor is a ligand-activated transcription factor (Wagage, 
2014) that is found in most nucleated cells of vertebrates, including mammals (Okey, 
2007). It has been suggested that the AhR is essential in multiple bodily processes such as 
cell growth and proliferation, differentiation, regulation of autoimmunity, inflammation, 
apoptosis and cancer progression (Moghe, 2013). As well, the AhR has been shown to 
have a roll in pluripotency and stemness (Roman et all., 2017). Though the AhR is shown 
to serve a role in immunity, how and why has been a subject to raise questions in the sci-
entific community since its discovery. There have been numerous suggestions of the 
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AhR’s purpose and roll, most of which having to do with mediating toxicity. Relevant lit-
erature suggests that the AhR suppresses cholera toxin specific immune response when 
activated as in the experimental model used here. 
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) 
 TCDD is a polychlorinated dibenzo-p-dioxin that will be used to activate the aryl 
hydrocarbon receptor. A number of endogenous and exogenous ligands can activate the 
AhR; TCDD being the most common exogenous chemical used to activate the AhR. 
TCDD has a 7-10 day half-life in mice and it has the highest affinity of all AhR activat-
ing compounds (Stejskalova et al, 2011). Previously, it has been shown that one large 
dose of TCDD suppresses a cholera toxin specific IgA response in feces and serum. Fig-
ure C exhibits results from previous studies which exposed mice to a single large dose of 
TCDD and the recovery of the antibody response over time.  
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 Cholera toxin is a complex of two units produced by the pathogen Vibrio cholerae 
and has been found to serve usefully in biology experimentation. It has been found that 
either alone or as an adjuvant for use with other antigens, cholera toxin exhibits a wide 
variety of application across many experimental fields (Wessling, 2017). Cholera toxin is 
comprised of varying units in its complex structure, the toxic “A” subunit causing mobil-
ity and mortality, where “B” protein subunits have been found to bind to the surface of 
mammalian target cells. Cholera toxin is unique in that it serves as both an antigen and 
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adjuvant. An adjuvant non-specifically enhances immune response, which serves usefully 
in experimental immunology. It has been shown that cholera toxin immunization 
“strongly potentiates the immunogenicity of most antigens” (Bharati, 2011). 
Dosage  
 Dose is often determined based off of the half-life of a drug (or the time that con-
centration of a given substance decreases by half). It is this determination of dose that af-
fects the behavior of a drug and the response to a drug. If dose is changed, toxicity, activ-
ity, and morbidity and mortality rates will also change. If it is assumed that dosage 
changes the toxicity and action of a drug, it can be predicted that varying doses will 
change the reaction seen, such as IgA and IgG levels (which will help determine the ef-
fects from activation of the AhR)..  It has been shown in previous experimentation that 
one, large dose (40 mcg/Kg concentration) of TCDD followed one day later with the first 
of four oral cholera toxin immunizations results in suppressed levels of CT-specific IgA. 
conjunction with an oral cholera toxin immunization model results in suppressed levels of 
CT-specific IgA. It then comes in to question if smaller doses, more frequently, using the 
same cholera toxin immunization regimen will produce a similar response. 
     Research Question 
 Does activation of the aryl receptor via weekly, low dose exposure to TCDD cause 
altered cholera-toxin specific IgA/IgG responses equivalent to that observed after a sin-
gle, high dose exposure? 
Assessing TCDD Dosages   15 
 
Hypothesis 
• Weekly low dose exposure to TCDD causes altered cholera-toxin specific IgA/IgG 
responses equivalent to that observed after a single high dose exposure. 
• Prediction 1:  Weekly low dose exposure to TCDD will initially cause suppression of 
serum and fecal CT-specific antibody levels equivalent to that seen after a single high 
dose exposure to TCDD. 
• Prediction 2: Recovery of CT-specific fecal antibody levels, but not serum antibody 
levels, will occur by four weeks after weekly low dose exposure to TCDD and single 







This study was carried out in strict accordance with the recommendations in the Guide 
for the Care and Use of Laboratory Animals of the National Institutes of Health. The pro-
tocol was approved by the Institutional Animal Care and Use Committee of the Univer-
sity of Northern Colorado.  All efforts were made to minimize suffering. 
Animals, immunizations, and treatments 
 The animals used were selected from the University of Northern Colorado animal 
facility. Female C57 mice between 6 and 8 weeks of age at the time of initial treatment 
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were used. 10 mice in total were used for each of the two trials of the experiment (3-4 an-
imals per treatment group). Each mouse was assigned an independent cage with standard 
food and water schedules maintained. Cholera Toxin immunization and TCDD treat-
ments were administered by Dr. Gregory DeKrey via gavage according to the time line 
attached. Animals were given peanut oil (Group 1) or TCDD as either three treatments 
(Group 2, 20 mcg/Kg total dose) or a single treatment (Group 3, 40 mcg/Kg total dose).   
 Weights were taken and recorded twelve times through the experiment as shown. 
Through both trials, there were no notable changes in weights in any of the mice (that 
would represent extreme stress and TCDD toxicity). 
Sample processing and analysis 
Fecal pellets were collected fresh after production by a mouse and lyophilized.  All ani-
mals were euthanized via CO2 overdose and serum was collected directly from the heart.  
Serum was separated from whole blood via centrifugation.  Lyophilized fecal pellets 
were extracted with saline.  Both serum and fecal extracts were analyzed for levels of an-
tibodies using an ELISA method as described by Lycke et al. (1999).  Data at each dilu-
tion were collected as optical density (OD) and used to compute areas under the curve 
(AUC) values for each animal.  Data are shown for samples collected three weeks after 
the initial treatment. 
Experimental Schedule 
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Day Group Treatment Obtained 
-1 All groups assigned 
treatment groups. And 
individual numbers. 
Heaviest and lightest 
mouse placed in 
control group. 
Individual cages 
chosen for each 
mouse, placed in one 
area in animal facility 
to prevent bias. Cages 
labelled with mouse # 
and treatment group. 
Weights obtained, 
recorded in grams.  
0 Control  Peanut oil 
administration based 
off weight.  
Weights obtained. 
0 Group 1 TCDD in concentration 
1mcg/mL given based 
off of weight 
Weights obtained.  
0 Group 2 TCDD in concentration 
4mcg/mL given based 
off of weight  
Weights obtained.  
1 All groups Cholera Toxin given 
based off weights 
Weights obtained 
7 Control  Peanut oil 
administration based 
off weight.  
Weights obtained 
7 Group 1 TCDD in concentration 
1mcg/mL given based 
off of weight 
Weights obtained 
7 Group 2  Peanut oil 
administration based 
off weight.  
Weights obtained 
8 All groups Cholera Toxin given 
based off weights 
Feces collected, 
frozen for future 
analysis. 
14 Control  Peanut oil 
administration based 
off weight.  
Weights obtained 
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Day Group Treatment Obtained 
14 Group 1 TCDD in concentration 
1mcg/mL given based 
off of weight 
Weights obtained 
14 Group 2 Peanut oil 
administration based 
off weight.  
Weights obtained 
15 All groups Cholera Toxin given 
based off weights 
Feces collected, 
frozen for future 
analysis. 
21 All groups  Necropsy Weights obtained, 
Feces collected & 
frozen. Serum 







Experiment 1 (averages only) 
Group  Control 
P.O. 




AUC average  
serum  
7.9495 8.0138 8.0173 
AUC average  
feces  
1.8675 0.4046 0.8076 
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Experiment 2 (averages only)  
Group  Control 
P.O. 




AUC average  
serum 
6.3406 0.9141 1.1180 
AUC average 
feces 




 The AhR exerts a modifying force on immune function when activated, suppress-
ing antibody. Suppression of antibody is useful in clinical application in instances such 
as: autoimmunity, graft, and organ rejection. For this reason, hypotheses included princi-
ples of toxicology and pharmacology.  Data from experiment 1 and 2 show similarities in 
terms of fecal antibody, as predicted from previous literature. It is shown that fecal anti-
body levels are consistently suppressed in both experiments, and there does not seem to 
be an obvious difference between TCDD groups. These data support the hypothesis that 
weekly low dose exposure to TCDD causes altered cholera-toxin specific IgA/IgG re-
sponses equivalent to that observed after a single high dose exposure. As the current 
pharmaceutical therapy model encourages small, frequent dosage times calculated based 
off of half life, this model will directly translate in to research on AhR activation. Though 
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neither TCDD groups exhibit toxicity in the 21 day experimental period, long term tox-
icity of a large dose model is possible, something to consider with the activation of the 
AhR.  It is unknown whether a small dose model lowers the probability for toxicity; how-
ever, given the trend of medicating, it is predicted that a small dose approach will be 
used. It was shown through these data that weekly low dose exposure to TCDD will ini-
tially case suppression of serum and fecal CT-specific antibody levels equivalent to that 
seen after a single high dose exposure to TCDD. 
 In previous research, it has been shown that fecal antibody levels can be 
suppressed via activation of the AhR; however, serum antibody levels do not respond in 
the same way as fecal antibody levels, regardless of their similar isotype population. This 
suggests that the activation of the AhR has differing affects throughout the body. In 
previous experimentation, it has been shown that we can suppress serum antibody levels 
similarly to fecal antibody levels, however, these levels to do not recover in the 21 day 
experimental window, as fecal antibody levels do. It was hypothesized and observed 
successfully that recovery of CT-specific fecal antibody levels, but not serum antibody 
levels, occurred by four weeks after weekly low dose exposure to TCDD and single high 
dose exposure. The serum antibody levels differ from experiment 1 to 2, unlike fecal 
values. The data from experiment 1 shows no suppression of serum levels, but more 
obvious suppression in the second experiment. It is consistent that in experiment 1 and 2  
Assessing TCDD Dosages   21 
 
that serum antibody levels do not recover in the 4 week period, validating the second pre-
diction. Serum, across experiments, shows a more unpredictable suppression of antibody 
levels than feces.  
 Through this experiment it has been shown that the activation of the AhR via 
TCDD in varying doses exudes a similar response, and recovers predictably in feces. Fur-
ther, it can be predicted that this same suppression is happening in serum, but, without re-
covery in the 21 day period, and varying between trails.  
Future Studies 
While the hypotheses were correct, consistent serum data will need to be produced and 
compared to further analyze clinical application. Additionally, a post antigen challenge 
model must be presented. These two ideas will give a better understanding of AhR acti-
vation throughout the body, and how those recover. A post antigen challenge model will 
also then be able to address if the AhR activation is similar in both sick (post antigen) and 
healthy (pre antigen) animals/ patients. 
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